全文获取类型
收费全文 | 407篇 |
免费 | 45篇 |
国内免费 | 12篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 5篇 |
基础医学 | 17篇 |
口腔科学 | 36篇 |
临床医学 | 15篇 |
内科学 | 42篇 |
神经病学 | 4篇 |
特种医学 | 2篇 |
外科学 | 167篇 |
综合类 | 56篇 |
预防医学 | 7篇 |
药学 | 96篇 |
中国医学 | 12篇 |
肿瘤学 | 2篇 |
出版年
2024年 | 1篇 |
2023年 | 4篇 |
2022年 | 3篇 |
2021年 | 12篇 |
2020年 | 12篇 |
2019年 | 8篇 |
2018年 | 15篇 |
2017年 | 10篇 |
2016年 | 7篇 |
2015年 | 10篇 |
2014年 | 22篇 |
2013年 | 53篇 |
2012年 | 31篇 |
2011年 | 32篇 |
2010年 | 20篇 |
2009年 | 38篇 |
2008年 | 29篇 |
2007年 | 23篇 |
2006年 | 30篇 |
2005年 | 22篇 |
2004年 | 11篇 |
2003年 | 9篇 |
2002年 | 16篇 |
2001年 | 10篇 |
2000年 | 10篇 |
1999年 | 11篇 |
1998年 | 8篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1993年 | 2篇 |
排序方式: 共有464条查询结果,搜索用时 15 毫秒
461.
目的:观察阿仑膦酸钠维D3联合滋肾骨康方对骨质疏松症患者的临床治疗效果。方法:将127例骨质疏松症患者按随机数字表法分成2组,对照组63例患者予以阿仑膦酸钠维D3进行治疗,观察组64例患者在对照组的基础上予以滋肾骨康方治疗。对比2组治疗前后骨密度、骨代谢指标和免疫功能的变化情况。结果:治疗后,观察组左股骨颈(LFN)、L1~4及左股骨粗隆骨密度明显高于对照组,差异有统计学意义(P<0.05);观察组人I型胶原交联氨基端肽(NTXI)、骨钙素(BGP)、25-羟基维生素(25-OHD)、β-胶原羧基端肽(β-CTX)水平明显优于对照组,差异有统计学意义(P<0.05)。观察组免疫功能指标IgM、IgG及中医症状综合评分明显优于对照组,差异均有统计学意义(P<0.05)。结论:阿仑膦酸钠维D3联合滋肾骨康方可以有效提高骨质疏松症患者的骨密度,改善骨代谢指标,增强患者的免疫功能,改善临床症状。 相似文献
462.
目的观察椎体成形术联合阿仑膦酸钠治疗老年骨折疏松性椎体压缩性骨折的近期临床治疗效果。方法选择本院老年骨质疏松性椎体压缩性骨折患者43例,所有患者均在C臂引导下行经皮椎体成形术,术后43例患者根据治疗方案不同分为对照组(n=20)和研究组(n=23),对照组采取常规使用钙剂及维生素D3抗骨质疏松治疗,研究组在对照组药物使用基础上加用阿仑膦酸钠抗骨质疏松治疗,疗程均为12个月。术前及术后不同随访时间点测骨密度(BMD);ELISA法检测血清骨保护素(OPG)变化情况;采用疼痛视觉模拟评分(VAS)评估患者疼痛程度;Oswestry功能障碍指数(ODI)评估活动能力,并分析骨折椎体高度及Cobb角变化情况。结果所有手术均顺利完成,术后安返病房,随访时间为13~21个月,平均16.7月。相比椎体成形术前,研究组患者术后3、6、12月较对照组BMD及OPG均有一定程度增高(0.05);经阿仑膦酸钠治疗3月后,研究组VAS评分及ODI评分均显著低于对照组,且后续不同随访时间点VAS评分及ODI评分均能有效维持(0.05)。相比椎体成形术前,所有患者术后椎体前缘高度、中部高度优于术前椎体高度(0.05);且治疗3月后,研究组椎体前缘高度、中部高度较优于对照组(0.05);相比对照组,研究组Cobb角明显减小(0.05)。结论椎体成形术联合阿仑酸钠治疗老年骨折疏松性椎体压缩性骨折效果较为显著,术后持续使用阿仑膦酸钠治疗能一定程度增加椎骨骨密度,抑制骨保护素的降低进而防止骨破坏,可有效治疗骨质疏松及预防骨质疏松性骨折再次发生,适合临床推广应用。 相似文献
463.
L.A.D. Nicolau R.O. Silva S.R.B. Damasceno N.S. Carvalho N.R.D. Costa K.S. Arag?o A.L.R. Barbosa P.M.G. Soares M.H.L.P. Souza J.V.R. Medeiros 《Brazilian journal of medical and biological research》2013,46(8):708-714
Our objective was to investigate the protective effect of Lawesson''s reagent, an
H2S donor, against alendronate (ALD)-induced gastric damage in rats.
Rats were pretreated with saline or Lawesson''s reagent (3, 9, or 27 µmol/kg,
po) once daily for 4 days. After 30 min, gastric damage was
induced by ALD (30 mg/kg) administration by gavage. On the last day of treatment, the
animals were killed 4 h after ALD administration. Gastric lesions were measured using
a computer planimetry program, and gastric corpus pieces were assayed for
malondialdehyde (MDA), glutathione (GSH), proinflammatory cytokines [tumor necrosis
factor (TNF)-α and interleukin (IL)-1β], and myeloperoxidase (MPO). Other groups were
pretreated with glibenclamide (5 mg/kg, ip) or with glibenclamide (5
mg/kg, ip)+diazoxide (3 mg/kg, ip). After 1 h, 27
µmol/kg Lawesson''s reagent was administered. After 30 min, 30 mg/kg ALD was
administered. ALD caused gastric damage (63.35±9.8 mm2); increased levels
of TNF-α, IL-1β, and MDA (2311±302.3 pg/mL, 901.9±106.2 pg/mL, 121.1±4.3 nmol/g,
respectively); increased MPO activity (26.1±3.8 U/mg); and reduced GSH levels
(180.3±21.9 µg/g). ALD also increased cystathionine-γ-lyase immunoreactivity in the
gastric mucosa. Pretreatment with Lawesson''s reagent (27 µmol/kg) attenuated
ALD-mediated gastric damage (15.77±5.3 mm2); reduced TNF-α, IL-1β, and MDA
formation (1502±150.2 pg/mL, 632.3±43.4 pg/mL, 78.4±7.6 nmol/g, respectively);
lowered MPO activity (11.7±2.8 U/mg); and increased the level of GSH in the gastric
tissue (397.9±40.2 µg/g). Glibenclamide alone reversed the gastric protective effect
of Lawesson''s reagent. However, glibenclamide plus diazoxide did not alter the
effects of Lawesson''s reagent. Our results suggest that Lawesson''s reagent plays a
protective role against ALD-induced gastric damage through mechanisms that depend at
least in part on activation of ATP-sensitive potassium (KATP)
channels. 相似文献
464.
《Saudi Dental Journal》2023,35(5):515-524
BackgroundPeriodontitis is a complex chronic inflammatory disease aggravated in immunosuppressed patients. However, adjuvant therapies can alleviate severe inflammation and slow down disease progression.ObjectiveTo evaluate the efficacy of myricitrin, a herbal flavonoid glycoside, in reducing immunosuppression-associated periodontitis and compare its effects with that of alendronate on alveolar bone regeneration.MethodsFifty albino Wistar rats were randomly allocated to the control, periodontitis, immunosuppressant, myricitrin, and alendronate groups. Ligature-associated periodontitis was induced in all groups, except the control group. Cyclosporin A (CsA) was administered subcutaneously in the immunosuppressant group for immunosuppression. The myricitrin group received CsA and myricitrin, whereas the alendronate group received CsA and alendronate. The therapeutic efficacies of myricitrin and alendronate were compared histologically, morphometrically, and biochemically.ResultsMyricitrin reversed bone destruction in the periodontitis and immunosuppressant groups. Morphometrically, myricitrin showed comparable improvements to alendronate in terms of gaining more bone area to 49.4 ± 4.6 and 59.5 ± 2%, respectively (P < 0.001 in relation to the untreated periodontitis group). Concomitantly, myricitrin increased osteoblast count significantly to 28.4 ± 4.7 closer to the 34.5 ± 2.4 count in the alendronate group (P < 0.001 compared with 22.5 ± 2.6 count of the immunosuppressant group). Moreover, myricitrin restored the serum calcium to 9.4 ± 0.6 mg/dL and alkaline phosphatase up to 112.9 ± 2.9 IU/L, which were almost normal levels similar to the control cohort (P > 0.05).ConclusionMyricitrin showed beneficial effects in counteracting bone resorption in subjects with immunosuppression-associated periodontitis. Its efficacy in slowing down disease progression was comparable to that of alendronate. 相似文献